Abstract
Our on-going screening program to discover new antitrypanosomal antibiotics has been evaluating compounds isolated from soil microorganisms as well as investigating the antibiotic libraries of the Kitasato Institute for Life Sciences and BioFrontier Laboratories of Kyowa Hakko Kogyo Co., Ltd. We have now discovered two compounds, KS-505a and alazopeptin, which exhibit moderate antitrypanosomal characteristics. We report here the in vitro and in vivo antitrypanosomal activities and cytotoxicities of KS-505a and alazopeptin, compared with some commonly-used antitrypanosomal drugs. This is the first report of in vitro and in vivo antitrypanosomal activities of either KS-505a or alazopeptin.
Similar content being viewed by others
Article PDF
References
WHO. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rep 81: 71–80 ( 2006)
Fairlamb AH . Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol 19: 488–494 ( 2003)
Matovu E, Seebeck T, Enyaru JCK, Kaminsky R . Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect 3: 763–770 ( 2001)
Brun R, Schumacher R, Schmid C, Kunz C, Burri C . The phenomenon of treatment failures in Human African Trypanosomiasis. Trop Med Int Health 6: 906–914 ( 2001)
Otoguro K, Ishiyama A, Namatame M, Nishihara A, Furusawa T, Masuma R, Shiomi K, Takahashi Y, Yamada H, Ōmura S . Selective and potent in vitro antitrypanosomal activities of ten microbial metabolites. J Antibiot 61: 372–378 ( 2008)
Cunningham MP, Vickerman K . Antigenic analysis in Trypanosoma brucei group using an agglutination reaction. Trans R Soc Trop Med Hyg 56: 48–59 ( 1962)
Baltz T, Baltz D, Giroud Ch, Crockett J . Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J 4: 1273–1277 ( 1985)
Otoguro K, Kohana A, Manabe C, Ishiyama A, Ui H, Shiomi K, Yamada H, Ōmura S . Potent antimalarial activities of polyether antibiotic, X-206. J Antibiot 54: 658–663 ( 2001)
Lanham S, Godfrey DG . Isolation of salivarian trypanosomes from man and other mammals using DEAECellulose. Exp Parasitol 28: 521–534 ( 1970)
Baliani A, Bueno GJ, Stewart ML, Yardley V, Brun R, Barrett MP, Gilbert IH . Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. J Med Chem 48: 5570–5579 ( 2005)
Nakanishi S, Osawa K, Saito Y, Kawamoto I, Kuroda K, Kase H . KS-505a, a novel inhibitor of bovine brain Ca+2 and calmodulin-dependent cyclic-nucleotide phosphodiesterase from Streptomyces argenteolus. J Antibiot 45: 341–347 ( 1992)
Nagashima K, Toki S, Nakanishi S, Kase H, Matsuda Y . Neurite formation in NG108-15 neuroblastoma×glioma hybrid cells by KS-505a, a potent inhibitor of brain cyclicnucleotide phosphodiesterase. J Antibiot 46: 1481–1483 ( 1993)
Ichimura M, Eiki R, Osawa K, Nakanishi S, Kase H . KS-505a, an isoform-selective inhibitor of calmodulindependent cyclic-nucleotide phosphodiesterase. Biochem J 316: 311–316 ( 1996)
Zoraghi R, Kunz S, Gong K, Seebeck T . Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the Protozoan parasite Trypanosoma brucei. J Biol Chem 276: 11559–11566 ( 2001)
Rascón A, Scoderling SH, Schaefer JB, Beavo JA . Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei. Proc Natl Acad Sci USA 99: 4714–4719 ( 2002)
Zoraghi R, Kunz S, Gong K, Seebeck T . The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream from Trypanosoma brucei. Proc Natl Acad Sci USA 99: 4343–4348 ( 2002)
Oberholzer M, Marti G, Beresic M, Kunz S, Hemphill A, Seebeck T . The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence. FASEB J 21: 720–731 ( 2007)
Petterson EL, Johnson BL, DeVoe SE, Bohonos N . Structure of the antitumor antibiotic alazopeptin. Antimicrob Agents Chemother 5: 115–118 ( 1965)
DeVoe SE, Rigler NE, Shay AJ, Martin JH, Boyd TC, Backus EJ, Mowat JH, Bohonos N . Alazopeptin; production, isolation, and chemical characteristics. Antibiotics Annual 1956–1957: 730–735
Hofer A, Steverding D, Chabes A, Brun R, Thelander L . Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness. Proc Natl Acad Sci USA 98: 6412–6416 ( 2001)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishiyama, A., Otoguro, K., Namatame, M. et al. In Vitro and in Vivo Antitrypanosomal Activitiy of Two Microbial Metabolites, KS-505a and Alazopeptin. J Antibiot 61, 627–632 (2008). https://doi.org/10.1038/ja.2008.83
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2008.83
Keywords
This article is cited by
-
Reaction mechanism of the farnesyl pyrophosphate C-methyltransferase towards the biosynthesis of pre-sodorifen pyrophosphate by Serratia plymuthica 4Rx13
Scientific Reports (2021)
-
Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model
Metabolic Brain Disease (2014)
-
In vitro antitrypanosomal activity of five low-MW antibiotics
The Journal of Antibiotics (2012)
-
Jogyamycin, a new antiprotozoal aminocyclopentitol antibiotic, produced by Streptomyces sp. a-WM-JG-16.2
The Journal of Antibiotics (2012)
-
In vitro antitrypanosomal activity of bis(bibenzyls)s and bibenzyls from liverworts against Trypanosoma brucei
Journal of Natural Medicines (2012)